Fournier A, Antoun F, Charlois Ou C, Muller G, Ezri L, Morin P, Faure A, Marteau D, Keshtmand H, Quelet S
Cellule tuberculose, département de Paris, sous-direction de la santé, DASES, centre de lutte antituberculeuse de Paris (CLAT 75), 15-17, rue Charles-Bertheau, 75013 Paris, France.
Cellule tuberculose, département de Paris, sous-direction de la santé, DASES, centre de lutte antituberculeuse de Paris (CLAT 75), 15-17, rue Charles-Bertheau, 75013 Paris, France.
Rev Mal Respir. 2015 Sep;32(7):705-14. doi: 10.1016/j.rmr.2014.06.031. Epub 2014 Nov 6.
To our knowledge, the proportion of active tuberculosis diagnosed after 12-18 months during a screening tuberculosis process in a specialized centre (centre de lutte antituberculeuse [CLAT]) has not been described in France. The majority of other countries do not have any recommendation to screen at this time.
We evaluated the number of treated or not treated latent tuberculosis infections (LTI) identified during tuberculosis screening. We identified the causes of ITL non-treatment, the number of active disease cases and the proportion of subjects lost to follow-up after 12-18 months.
Among the 1066 contact subjects, 159 (15 %) had a positive QuantiFERON-TB-Gold In-Tube(®) test. A prophylactic treatment with Rifinah(®) was given to 97 (61 %) subjects, 7 (7.3 %) having developed side effects that led to treatment interruption. A high proportion (56 %) of contact subjects were lost of follow-up and the main reason for no prophylactic treatment (20/52, 38 %) was due to these losses. No active disease cases were identified among the 474 (44 %) contact subjects who had a chest X-ray after 12-18 months follow-up by the CLAT. The low level of positive QuantiFERON-TB-Gold In-Tube(®) tests (15 %) could be explained by the high specificity of this test and the strong proportion of occupational contacts, of whom a probably significant number were not exposed to active disease.
The absence of active disease at 12-18 months and a majority (56 %) of contact subjects lost from follow-up at this period let us propose not to recall contact subjects at 12-18 months with the exception of those living under the same roof as the index case and/or those having a cumulative contact time of greater than 100 hours during the theoretical infectious period. This proposal remains to be confirmed by other studies, particularly including possible secondary cases diagnosed outside the screening periods by the CLAT.
据我们所知,法国尚未描述在专门的结核病防治中心(CLAT)进行结核病筛查过程中,12至18个月后诊断出的活动性结核病比例。目前大多数其他国家没有进行此类筛查的建议。
我们评估了结核病筛查期间确定的接受或未接受治疗的潜伏性结核感染(LTI)数量。我们确定了未治疗ITL的原因、活动性疾病病例数以及12至18个月后失访的受试者比例。
在1066名接触者中,159人(15%)的全血γ干扰素释放试验(QuantiFERON-TB-Gold In-Tube(®))呈阳性。97名(61%)受试者接受了利福平(Rifinah(®))预防性治疗,7名(7.3%)出现副作用导致治疗中断。高比例(56%)的接触者失访,未进行预防性治疗的主要原因(20/52,38%)是这些失访情况。在CLAT进行12至18个月随访后进行胸部X光检查的474名(44%)接触者中,未发现活动性疾病病例。全血γ干扰素释放试验(QuantiFERON-TB-Gold In-Tube(®))阳性率低(15%)可能是由于该试验的高特异性以及职业接触者比例较高,其中可能有相当数量的人未接触到活动性疾病。
12至18个月时未出现活动性疾病,且在此期间大多数(56%)接触者失访,这让我们建议,除了与索引病例同住一个屋檐下的人以及/或在理论传染期内累计接触时间超过100小时的人外,请不要在12至18个月时召回接触者。这一建议仍有待其他研究证实,特别是包括CLAT在筛查期外诊断出的可能的二代病例。